These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9613562)

  • 1. No evidence for increased frequency of autoantibodies during interferon-beta1b treatment of multiple sclerosis.
    Kivisäkk P; Lundahl J; von Heigl Z; Fredrikson S
    Acta Neurol Scand; 1998 May; 97(5):320-3. PubMed ID: 9613562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No increase of serum autoantibodies during therapy with recombinant human interferon-beta1a in relapsing-remitting multiple sclerosis.
    Colosimo C; Pozzilli C; Frontoni M; Farina D; Koudriavtseva T; Gasperini C; Salvetti M; Valesini G
    Acta Neurol Scand; 1997 Dec; 96(6):372-4. PubMed ID: 9449474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoantibodies in multiple sclerosis patients before and during IFN-beta 1b treatment: are they correlated with the occurrence of autoimmune diseases?
    Verdun E; Isoardo G; Oggero A; Ferrero B; Ghezzi A; Montanari E; Zaffaroni M; Durelli L;
    J Interferon Cytokine Res; 2002 Feb; 22(2):245-55. PubMed ID: 11911808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discordant effect of IFN-beta1a therapy on anti-IFN antibodies and thyroid disease development in patients with multiple sclerosis.
    Monzani F; Meucci G; Caraccio N; Saviozzi M; Casolaro A; Moscato G; Lombardo F; Mosti S; Scagnolari C; Bruschi F; Antonelli G; Ferrannini E; Murri L
    J Interferon Cytokine Res; 2002 Jul; 22(7):773-81. PubMed ID: 12184915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arthritis during interferon beta-1b treatment in multiple sclerosis.
    Altintas A; Alici Y; Melikoğlu M; Siva A
    Mult Scler; 2002 Dec; 8(6):534-6. PubMed ID: 12474998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Interferon-β1b in multiple sclerosis therapy: more than 20 years clinical experience].
    Hartung HP; Haas J; Meergans M; Tracik F; Ortler S
    Nervenarzt; 2013 Jun; 84(6):679-704. PubMed ID: 23669866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Appearance of immune thyroid diseases during beta-interferon therapy of multiple sclerosis].
    Buchinger W; Niederwieser G; Rainer F
    Dtsch Med Wochenschr; 1999 Dec; 124(48):1473. PubMed ID: 10615332
    [No Abstract]   [Full Text] [Related]  

  • 8. CD45RA+ ICAM-3+ lymphocytes in interferon-beta1b-treated and -untreated patients with relapsing-remitting multiple sclerosis.
    Chatzimanolis N; Kraus J; Bauer R; Engelhardt B; Bregenzer T; Kuehne BS; Tofighi J; Laske C; Stolz E; Blaes F; Voigt K; Traupe H; Kaps M; Oschmann P
    Acta Neurol Scand; 2004 Dec; 110(6):377-85. PubMed ID: 15527450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralising and binding anti-interferon-beta-I b (IFN-beta-I b) antibodies during IFN-beta-I b treatment of multiple sclerosis.
    Kivisäkk P; Alm GV; Tian WZ; Matusevicius D; Fredrikson S; Link H
    Mult Scler; 1997 Jun; 3(3):184-90. PubMed ID: 9310964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of 1-year treatment with interferon-beta1b on thyroid function and autoimmunity in patients with multiple sclerosis.
    Monzani F; Caraccio N; Meucci G; Lombardo F; Moscato G; Casolaro A; Ferdeghini M; Murri L; Ferrannini E
    Eur J Endocrinol; 1999 Oct; 141(4):325-31. PubMed ID: 10526243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis.
    Weber F; Polak T; Günther A; Kubuschok B; Janovskaja J; Bitsch A; Poser S; Rieckmann P
    Ann Neurol; 1998 Jul; 44(1):27-34. PubMed ID: 9667590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-beta1b for multiple sclerosis.
    Burks J
    Expert Rev Neurother; 2005 Mar; 5(2):153-64. PubMed ID: 15853486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of binding and neutralising antibodies to interferon-beta in two groups of relapsing-remitting multiple sclerosis patients.
    Fernández O; Mayorga C; Luque G; Guerrero M; Guerrero R; Leyva L; León A; Blanca M
    J Neurol; 2001 May; 248(5):383-8. PubMed ID: 11437159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term treatment of relapsing remitting multiple sclerosis patients with interferon (IFN)-beta1B transiently increases the blood levels of interleukin (IL)-6, IL-10 and IFN-gamma without significantly modifying those of IL-1beta, IL-2, IL-4 and tumour necrosis factor-alpha.
    Nicoletti F; Di Marco R; Patti F; Zaccone P; L'Episcopo MR; Reggio E; Xiang M; Nicoletti A; Reggio A
    Cytokine; 2000 Jun; 12(6):682-7. PubMed ID: 10843745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-beta 1b leads to a short-term increase of soluble but long-term stabilisation of cell surface bound adhesion molecules in multiple sclerosis.
    Kraus J; Bauer R; Chatzimanolis N; Engelhardt B; Tofighi J; Bregenzer T; Kuehne BS; Stolz E; Blaes F; Morgen K; Traupe H; Kaps M; Oschmann P
    J Neurol; 2004 Apr; 251(4):464-72. PubMed ID: 15083294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy.
    Sorensen PS; Koch-Henriksen N; Ross C; Clemmesen KM; Bendtzen K;
    Neurology; 2005 Jul; 65(1):33-9. PubMed ID: 15888603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum auto antibodies presence in multiple sclerosis patients treated with beta-interferon 1a and 1b.
    Speciale L; Saresella M; Caputo D; Ruzzante S; Mancuso R; Calvo MG; Guerini FR; Ferrante P
    J Neurovirol; 2000 May; 6 Suppl 2():S57-61. PubMed ID: 10871787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-beta1b in multiple sclerosis: effect on progression of disability and clinical markers of treatment response.
    Carmona O; Casado V; Moral E; Alonso-Magdalena L; Martínez-Yélamos A; Martínez-Yélamos S; Martín-Ozaeta G; Arbizu T
    Eur Neurol; 2008; 60(6):279-84. PubMed ID: 18824855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing antibodies to interferon.
    Noronha A
    Neurology; 2007 Jun; 68(24 Suppl 4):S16-22. PubMed ID: 17562846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should neutralizing antibodies be monitored during interferon-beta treatment for multiple sclerosis?
    Oger J; Gibbs E
    Nat Clin Pract Neurol; 2006 Feb; 2(2):76-7. PubMed ID: 16932528
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.